Krystal Biotech (KRYS) Stock Price

Krystal Biotech Price

NASDAQ·CLOSED
322.58USD+1.73 (+0.54 %)
Market closed

Revenue has compounded at 133.5% per year over the past 7 years to 389.13 M USD. Earnings per share have grown at 324.6% per year over the last 2 years. Krystal Biotech's net margin stands at 52.6%, up from -1,060.3% several years earlier. Analysts set a median price target of 316.20 USD, implying 2.0% below the current price. Of 18 analysts, 17 rate the stock a buy — an overall Buy consensus. The stock trades about 137% above its 52-week low.

Krystal Biotech stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Krystal Biotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Krystal Biotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Krystal Biotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Krystal Biotech Stock Price History
DateKrystal Biotech Price
8/5/2026322.58 USD
8/4/2026320.86 USD
8/3/2026312.57 USD
7/31/2026341.12 USD
7/30/2026366.85 USD
7/29/2026362.00 USD
7/27/2026336.60 USD
7/23/2026327.50 USD
7/22/2026336.80 USD
7/21/2026339.06 USD
7/20/2026339.22 USD
7/17/2026354.86 USD
7/16/2026341.79 USD
7/15/2026350.24 USD
7/14/2026339.43 USD
7/13/2026361.23 USD
7/10/2026365.81 USD
7/9/2026371.24 USD
7/8/2026373.80 USD
7/7/2026368.60 USD
7/6/2026374.00 USD
7/2/2026375.07 USD
7/1/2026371.58 USD
6/30/2026371.67 USD
6/29/2026373.78 USD
6/26/2026372.25 USD
6/25/2026359.93 USD
6/24/2026347.63 USD
6/23/2026340.21 USD
6/22/2026347.80 USD
6/18/2026347.76 USD
6/17/2026340.10 USD
6/16/2026323.42 USD
6/15/2026320.58 USD
6/12/2026324.84 USD
6/11/2026322.52 USD
6/10/2026314.57 USD
6/9/2026309.75 USD
6/8/2026301.76 USD
6/5/2026308.15 USD
6/4/2026310.81 USD
6/3/2026302.07 USD
6/2/2026293.03 USD
6/1/2026302.77 USD
5/29/2026310.80 USD
5/28/2026308.54 USD
5/27/2026305.32 USD
5/26/2026300.74 USD
5/22/2026303.10 USD
5/21/2026300.32 USD
5/20/2026298.68 USD
5/19/2026293.30 USD
5/18/2026291.75 USD
5/15/2026306.29 USD
5/14/2026316.30 USD
5/13/2026312.58 USD
5/12/2026310.31 USD
5/11/2026312.88 USD
5/8/2026305.71 USD
5/7/2026296.70 USD
5/6/2026288.99 USD
5/5/2026284.57 USD
5/4/2026286.95 USD
5/1/2026266.04 USD
4/30/2026262.26 USD
4/29/2026259.95 USD
4/28/2026269.27 USD
4/27/2026272.75 USD
4/24/2026272.52 USD
4/23/2026268.04 USD
4/22/2026275.94 USD
4/21/2026272.66 USD
4/20/2026276.50 USD
4/17/2026274.21 USD
4/16/2026264.06 USD
4/15/2026268.54 USD
4/14/2026270.00 USD
4/13/2026267.41 USD
4/10/2026259.00 USD
4/9/2026258.33 USD
4/8/2026264.22 USD
4/7/2026263.99 USD
4/6/2026261.80 USD
4/2/2026260.95 USD
4/1/2026258.91 USD
3/31/2026258.32 USD
3/30/2026246.94 USD
3/27/2026245.39 USD
3/26/2026251.40 USD
3/25/2026254.95 USD
3/24/2026247.09 USD
3/23/2026250.08 USD
3/20/2026251.68 USD
3/19/2026258.00 USD
3/18/2026250.83 USD
3/17/2026256.33 USD
3/16/2026250.16 USD
3/13/2026247.26 USD
3/12/2026251.31 USD
3/11/2026255.00 USD
3/10/2026261.08 USD
3/9/2026258.65 USD
3/6/2026253.69 USD
3/5/2026260.33 USD
3/4/2026265.00 USD
3/3/2026263.80 USD
3/2/2026258.81 USD
2/27/2026275.64 USD
2/26/2026276.36 USD
2/25/2026272.50 USD
2/24/2026266.90 USD
2/23/2026274.59 USD
2/20/2026261.80 USD
2/19/2026262.67 USD
2/18/2026283.29 USD
2/17/2026287.84 USD
2/13/2026276.45 USD
2/12/2026270.26 USD
2/11/2026272.65 USD
2/10/2026270.70 USD
2/9/2026272.61 USD
2/6/2026272.74 USD
2/5/2026267.64 USD
2/4/2026269.13 USD
2/3/2026279.57 USD
2/2/2026282.27 USD
1/30/2026279.24 USD
1/29/2026279.34 USD
1/28/2026272.91 USD
1/27/2026277.36 USD
1/26/2026278.75 USD
1/23/2026281.53 USD
1/22/2026289.13 USD
1/21/2026286.00 USD
1/20/2026274.81 USD
1/16/2026285.04 USD
1/15/2026282.01 USD
1/14/2026291.79 USD
1/13/2026291.93 USD
1/12/2026272.13 USD
1/9/2026261.41 USD
1/8/2026248.91 USD
1/7/2026246.37 USD
1/6/2026249.39 USD
1/5/2026244.71 USD
1/2/2026246.91 USD
12/31/2025246.54 USD
12/30/2025247.88 USD
12/29/2025253.68 USD
12/26/2025252.17 USD
12/24/2025251.29 USD
12/23/2025253.36 USD
12/22/2025249.61 USD
12/19/2025240.80 USD
12/18/2025233.37 USD
12/17/2025235.80 USD
12/16/2025238.55 USD
12/15/2025242.98 USD
12/12/2025244.65 USD
12/11/2025246.78 USD
12/10/2025239.72 USD
12/9/2025234.64 USD
12/8/2025234.05 USD
12/5/2025234.13 USD
12/4/2025221.96 USD
12/3/2025217.46 USD
12/2/2025215.06 USD
12/1/2025215.11 USD
11/28/2025218.00 USD
11/26/2025218.70 USD
11/25/2025216.97 USD
11/24/2025214.89 USD
11/21/2025212.02 USD
11/20/2025204.23 USD
11/19/2025204.10 USD
11/18/2025204.74 USD
11/17/2025208.25 USD
11/14/2025206.16 USD
11/13/2025201.21 USD
11/12/2025203.03 USD
11/11/2025203.00 USD
11/10/2025199.53 USD
11/7/2025197.93 USD
11/6/2025199.97 USD
11/5/2025199.88 USD
11/4/2025203.26 USD
11/3/2025197.85 USD
10/31/2025197.51 USD
10/30/2025189.08 USD
10/29/2025185.05 USD
10/28/2025189.65 USD
10/27/2025189.93 USD
10/24/2025186.13 USD
10/23/2025186.45 USD
10/22/2025186.42 USD
10/21/2025190.78 USD
10/20/2025195.96 USD
10/17/2025190.23 USD
10/16/2025188.33 USD
10/15/2025192.99 USD
10/14/2025188.05 USD
10/13/2025184.74 USD
10/10/2025181.47 USD
10/9/2025188.76 USD
10/8/2025187.18 USD
10/7/2025183.02 USD
10/6/2025180.57 USD
10/3/2025183.36 USD
10/2/2025181.69 USD
10/1/2025179.61 USD
9/30/2025176.53 USD
9/29/2025176.75 USD
9/26/2025167.82 USD
9/25/2025161.15 USD
9/24/2025162.00 USD
9/23/2025164.97 USD
9/22/2025165.42 USD
9/19/2025163.57 USD
9/18/2025160.61 USD
9/17/2025154.05 USD
9/16/2025154.38 USD
9/15/2025155.71 USD
9/12/2025143.68 USD
9/11/2025144.36 USD
9/10/2025137.46 USD
9/9/2025141.21 USD
9/8/2025145.20 USD
9/5/2025150.27 USD
9/4/2025149.75 USD
9/3/2025150.20 USD
9/2/2025149.00 USD
8/29/2025147.70 USD
8/28/2025150.76 USD
8/27/2025147.64 USD
8/26/2025146.88 USD
8/25/2025146.77 USD
8/22/2025150.49 USD
8/21/2025145.70 USD
8/20/2025145.86 USD
8/19/2025143.96 USD
8/18/2025146.30 USD
8/15/2025150.27 USD
8/14/2025150.33 USD
8/13/2025149.34 USD
8/12/2025143.62 USD
8/11/2025137.54 USD
8/8/2025138.66 USD
8/7/2025136.10 USD
Access this data via the Eulerpool API
Get Free API Key

Krystal Biotech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
50.70 M USD
-109.73 M USD
10.93 M USD
Jan 1, 2024
290.52 M USD
65.70 M USD
89.16 M USD
Jan 1, 2025
389.13 M USD
161.30 M USD
204.83 M USD
Jan 1, 2026 (e)
513.61 M USD
189.23 M USD
217.63 M USD
Jan 1, 2027 (e)
653.68 M USD
240.83 M USD
275.33 M USD
Jan 1, 2028 (e)
849.36 M USD
312.92 M USD
358.55 M USD
Jan 1, 2029 (e)
1.35 B USD
495.83 M USD
704.70 M USD
Jan 1, 2030 (e)
1.76 B USD
647.95 M USD
973.76 M USD

Krystal Biotech Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 4:36 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e
–––––––0.050.290.390.510.650.851.351.76
––––––––480.0034.1431.8827.2930.0258.4230.71
––36,000.00––––94.0093.1092.5492.5492.5492.5492.5492.54
0.360.360.360.36–––0.050.270.360.470.600.791.241.63
-1.00-4.00-11.00-22.00-32.00-68.00-145.00-109.0065.00161.00189.00240.00312.00495.00647.00
––-1,100.00––––-218.0022.4141.3936.8436.7536.7536.8036.80
-1.00-7.00-10.00-19.00-32.00-69.00-139.0010.0089.00204.00217.00275.00358.00704.00973.00
–600.0042.8690.0068.42115.63101.45-107.19790.00129.216.3726.7330.1896.6538.21
4.2810.3113.5717.3420.0222.2025.5628.8229.8829.9529.9529.9529.9529.9529.95
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Krystal Biotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Krystal Biotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Krystal Biotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Krystal Biotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Krystal Biotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Krystal Biotech stock margins

The Krystal Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Krystal Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Krystal Biotech.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
92.61 %
- %
- %
Jan 1, 2022
92.61 %
- %
- %
Jan 1, 2023
93.90 %
-216.43 %
21.56 %
Jan 1, 2024
93.09 %
22.61 %
30.69 %
Jan 1, 2025
92.61 %
41.45 %
52.64 %
Jan 1, 2026 (e)
92.61 %
36.84 %
42.37 %
Jan 1, 2027 (e)
92.61 %
36.84 %
42.12 %
Jan 1, 2028 (e)
92.61 %
36.84 %
42.21 %

Krystal Biotech Stock Revenue, EBIT, Earnings per Share

The Krystal Biotech earnings per share therefore indicates how much revenue Krystal Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 USD
-3.07 USD
-3.13 USD
Jan 1, 2022
0.00 USD
-5.68 USD
-5.48 USD
Jan 1, 2023
1.76 USD
-3.81 USD
0.38 USD
Jan 1, 2024
9.72 USD
2.20 USD
2.98 USD
Jan 1, 2025
12.99 USD
5.39 USD
6.84 USD
Jan 1, 2026 (e)
17.71 USD
6.32 USD
7.50 USD
Jan 1, 2027 (e)
22.54 USD
8.04 USD
9.49 USD
Jan 1, 2028 (e)
29.29 USD
10.45 USD
12.36 USD

Krystal Biotech business model & stock analysis

Krystal Biotech Inc was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. The company specializes in the development and commercialization of gene therapy products. It has several divisions, including dermatological and musculoskeletal diseases, as well as Ebenezer and X-Linked Retinoschisis. In the history of the company, there have been several milestones. In 2017, the company completed its first financing round, raising $8 million. In the same year, it became the first company to successfully treat a patient with its gene therapy for epidermolysis bullosa. This was a major breakthrough as this disease is otherwise difficult to treat. In 2018, the company went public on the Nasdaq, raising over $50 million. In 2019, Krystal Biotech began developing a gene therapy product for hereditary angioedema. The company's business model is primarily based on the discovery and development of gene therapy products targeting genetic defects. The goal is to treat diseases that are otherwise difficult or impossible to treat. Krystal Biotech emphasizes that it follows a patient-centric approach in the development of its gene therapy products. Another part of the business model is collaborating with partner companies and institutions to advance the development and commercialization of its products. Krystal Biotech Inc has several divisions. The first division focuses on dermatological diseases. Its gene therapy products are designed to treat epidermolysis bullosa and Netherton syndrome. Epidermolysis bullosa is a rare disease caused by a mutation in collagen and other proteins, leading to blistering and lesions on the skin. Netherton syndrome is a disease that can also cause skin rashes and allergic reactions. Krystal Biotech offers gene therapy products to reduce the symptoms of these diseases and improve patients' quality of life. Another division is musculoskeletal diseases. Krystal Biotech Inc has developed gene therapy products to treat patients with osteoarthritis and sickle cell anemia. Osteoarthritis is a painful condition caused by the breakdown of cartilage in the joint. The gene therapy products offered by Krystal Biotech are intended to promote the regeneration of cartilage cells and support joint preservation. Sickle cell anemia is an inherited disease that causes red blood cells to have an abnormal shape and can block blood vessels. Krystal Biotech's gene therapy products are intended to reduce the risk of painful crises caused by this condition. Another division of Krystal Biotech is Ebenezer and X-Linked Retinoschisis. This is an inherited condition that affects vision. Krystal Biotech has developed gene therapy products to treat this problem. Overall, Krystal Biotech Inc has conducted promising research projects. The company has core expertise in gene therapy and can apply its innovations to various medical fields. The gene therapy products offered by Krystal Biotech are intended to improve patients' lives and treat diseases that are otherwise difficult to cure.

Krystal Biotech SWOT Analysis

Strengths

Krystal Biotech Inc possesses several unique strengths that contribute to its competitive advantage in the biotech industry. Firstly, the company has a strong research and development team comprising highly skilled scientists and experts. Their expertise allows Krystal Biotech to continuously innovate and develop cutting-edge gene therapy products.

Another key strength of Krystal Biotech is its proprietary technology platforms. The company's advanced gene delivery system enables efficient and targeted delivery of genetic therapies, offering potential breakthrough treatments for various diseases. This technology provides a significant advantage over competitors.

Weaknesses

Despite its strengths, Krystal Biotech Inc faces some weaknesses that could impact its performance. One notable weakness is the company's relatively small scale compared to larger biotech firms. Limited resources and infrastructure may hinder the company's ability to quickly scale up production or compete on the same level as industry giants.

Additionally, as a relatively young company, Krystal Biotech may lack the extensive market experience and established partnerships that larger competitors possess. This could make it more challenging for the company to penetrate new markets or negotiate favorable business deals.

Opportunities

Krystal Biotech Inc operates in an industry with vast opportunities for growth. The increasing demand for gene therapy products and personalized medicine presents a significant opportunity for the company to expand its market presence and generate substantial revenue.

Furthermore, Krystal Biotech can explore strategic collaborations with academic institutions and other biotech companies to leverage shared resources, expertise, and enhance research capabilities. Such partnerships can lead to accelerated development of new therapies, paving the way for additional revenue streams and market collaborations.

Threats

Despite the opportunities, Krystal Biotech also faces certain threats that could impact its competitive position. One such threat is the highly regulated nature of the biotech industry. Stringent regulatory processes and compliance requirements can result in delays or even failure in obtaining necessary approvals for product commercialization.

Additionally, potential competition from established biotech companies and emerging startups poses a threat to Krystal Biotech's market share. The industry's rapid pace of innovation means that competitors may quickly develop similar gene therapies, potentially eroding the company's competitive advantage.

Krystal Biotech Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Krystal Biotech Employees
Details
Date
Krystal Biotech Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Krystal Biotech Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Krystal Biotech historical P/E ratio, EBIT multiple, and P/S ratio

Krystal Biotech annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Krystal Biotech shares outstanding

The number of shares of Krystal Biotech was 29.95 M in 2025. This indicates how many shares Krystal Biotech is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
22.20 M Stocks
Jan 1, 2022
25.56 M Stocks
Jan 1, 2023
28.82 M Stocks
Jan 1, 2024
29.88 M Stocks
Jan 1, 2025
29.95 M Stocks
Jan 1, 2026 (e)
29.95 M Stocks
Jan 1, 2027 (e)
29.95 M Stocks
Jan 1, 2028 (e)
29.95 M Stocks

Current Krystal Biotech forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
7.64 %
Buy
94.44 % (17)
Hold
5.56 % (1)
Sell
0.00 % (0)
12M Price Target
316.20
Last Price
322.69
Currency
USD
12M Return Potential
-2.01 %
LTM Return
0 %

Krystal Biotech Analyst Rating Actions

DateFirmActionRatingReliability
7/14/2026
B of A Securities
B of A Securities
MaintainedBuy70
6/18/2026
TD Cowen
TD Cowen
MaintainedBuy60
6/16/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
6/1/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/22/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/18/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/5/2026
Evercore ISI Group
Evercore ISI Group
MaintainedOutperform62
5/5/2026
Citigroup
Citigroup
MaintainedBuy48
5/4/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
2/25/2026
Guggenheim
Guggenheim
MaintainedBuy30

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Krystal Biotech Earnings Calls

2025

Krystal Biotech Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/10/20261.75USD-125.33 MUSD-2026 Q2
5/11/20261.43USD-114.17 MUSD-2026 Q1
3/2/20261.44USD-107.56 MUSD-2025 Q4
5/6/2024-0.33USD-34.20 MUSD-2024 Q1
2/26/2024-0.44USD-29.16 MUSD-2023 Q4
11/6/2023-1.42USD-8.36 MUSD-2023 Q3
8/7/2023-1.53USD-3.62 MUSD-2023 Q2
5/8/2023-0.77USD-778,839.00USD-2023 Q1
2/27/2023-1.35USD-0.00USD-2022 Q4
11/7/2022-1.24USD-0.00USD-2022 Q3

EESG©

Eulerpool ESG Scorecard© for the Krystal Biotech stock

65/100
53
Environment
75
Social
67
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Krystal Biotech shareholder structure

% Name
15.08271%
FMR LLC
FMR LLC
13.58778%
BLACKROCK, INC.
BLACKROCK, INC.
9.96168%
AVORO CAPITAL ADVISORS LLC
AVORO CAPITAL ADVISORS LLC
5.02320%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
4.53253%
STATE STREET CORP
STATE STREET CORP
4.01836%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
...

Krystal Biotech Beneficial Ownership Filings (SEC 13D/G)

Free Float
79.4%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
19.90%
19.9% (2)
19.9% (2)
SEC ↗
12.10%
12.1%(2)
12.1%(2)
SEC ↗
11.50%
Suma M. Krishnan
Suma M. Krishnan
SEC ↗
11.50%
Krish S. Krishnan
Krish S. Krishnan
SEC ↗
8.64%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
8.50%
Redmile Group, LLC
Redmile Group, LLC
SEC ↗
8.50%
Jeremy C. Green
Jeremy C. Green
SEC ↗
6.80%
RA Capital Management, LLC
RA Capital Management, LLC
SEC ↗
6.80%
Peter Kolchinsky
Peter Kolchinsky
SEC ↗
6.63%
Select Biotechnology Portfolio
Select Biotechnology Portfolio
SEC ↗

Krystal Biotech Executives and Management Board

11 members · avg. age 60 · 36 % women

KK

Mr. Krish Krishnan (60)

Chairman of the Board, President, Chief Executive Officer · since 2016

15.60 M USD

Management

SK

Ms. Suma Krishnan (60)

President - Research and Development, Founder, Director · since 2016

8.24 M USD
KR

Ms. Kathryn Romano (44)

Chief Accounting Officer

3.05 M USD
MD

Ms. Meg Dodge

Investor Relations · since 2022

–

Board of Directors

DJ

Mr. Daniel Janney (59)

Lead Independent Director

702,694.00 USD
JG

Mr. Julian Gangolli (67)

Independent Director

670,194.00 USD
DR

Mr. Dino Rossi (70)

Independent Director

670,194.00 USD
ES

Dr. Everett Sutherland (55)

Independent Director

655,194.00 USD
CM

Ms. Catherine Mazzacco (60)

Independent Director

650,194.00 USD
AM

Dr. Adm. Christopher Mason (67)

Independent Director

648,194.00 USD

Frequently asked questions about Krystal Biotech

Krystal Biotech Inc is a biopharmaceutical company specializing in gene therapies. Their business model focuses on developing and commercializing innovative treatments to address severe dermatological diseases. By harnessing the power of gene therapy, Krystal Biotech aims to provide targeted and sustainable solutions for patients, offering potential long-term benefits. With a strong emphasis on cutting-edge research and development, they strive to revolutionize the treatment landscape by creating novel therapies that address unmet medical needs. Krystal Biotech Inc's business model is driven by a commitment to scientific excellence and a passion for improving the lives of patients suffering from dermatological conditions.

Krystal Biotech Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Krystal Biotech Inc in the market include companies such as Regenxbio Inc, bluebird bio Inc, and Sangamo Therapeutics Inc. These companies have a similar focus on gene therapy and are actively engaged in the development and commercialization of innovative treatments for genetic diseases. Krystal Biotech Inc competes with these companies in terms of research, development, and market adoption of gene therapy products.

Krystal Biotech Inc, headquartered in Pittsburgh, Pennsylvania, is a clinical-stage gene therapy company focused on developing and commercializing transformative treatments for patients suffering from rare genetic diseases. Founded in 2015, Krystal Biotech is driven by a mission to deliver potentially curative therapies that address the unmet medical needs of patients worldwide. Leveraging its proprietary Skin TARgeted Delivery platform, the company aims to develop innovative gene therapies for dermatological conditions, starting with its lead product candidate, KB105. Through strategic collaborations, Krystal Biotech strives to revolutionize the treatment landscape by advancing gene therapies to provide hope for patients and their families.

Krystal Biotech Inc has achieved several significant milestones. One of the notable achievements includes the successful completion of the phase 2 clinical trial for their gene therapy product, known as KB103. This product aims to treat a rare skin disorder called dystrophic epidermolysis bullosa (DEB). Additionally, the company has also achieved positive results in pre-clinical trials for other gene therapy candidates, showcasing their potential to address various genetic disorders. Krystal Biotech Inc has received several grants and awards for their innovative research and development efforts. These achievements highlight the promising growth and potential of Krystal Biotech Inc in the field of gene therapy.

Krystal Biotech Inc is primarily present in the United States.

Krystal Biotech Inc represents values of innovation, dedication, and excellence in the field of biotechnology. The company is committed to developing and delivering advanced gene therapies to treat rare skin diseases. With a vision to transform lives, Krystal Biotech focuses on providing effective and safe solutions that address unmet medical needs. Their corporate philosophy revolves around promoting patient-centric care, scientific rigor, and ethical practices. By leveraging cutting-edge technology and scientific expertise, Krystal Biotech strives to enhance the quality of life for individuals affected by genetic skin disorders.

Analysts currently set an average price target of 296.63 USD for the Krystal Biotech stock (median: 316.20 USD), implying -8.1 % versus the latest price. The consensus is based on 18 analyst ratings.

Krystal Biotech Analyst Price Targets 2026

18 analysts currently rate the Krystal Biotech stock: 17 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Krystal Biotech to generate revenue of 513.61 M USD and earnings per share of 7.27 USD.

Krystal Biotech Analyst Price Targets 2026

Converted at the current exchange rate, the Krystal Biotech share trades at 279.78 EUR (322.58 USD).

The Krystal Biotech share (KRYS) is listed on 4 stock exchanges, including: NASDAQ (KRYS), Frankfurt (4KB.F), München (4KB.MU), Düsseldorf (4KB.DU).

Krystal Biotech Inc is a biotechnology company focused on developing gene therapy products for rare dermatology and genetic diseases. The company aims to develop innovative therapies that improve the lives of patients with rare diseases. The business model is based on the development and commercialization of gene therapy products. Krystal Biotech uses a proprietary gene therapy platform called HSV-1 vector to develop therapies for serious and rare dermatological conditions such as Epidermolysis bullosa, Netherton syndrome, and Heidelberg syndrome. The company's gene therapy products utilize the HSV-1 vector's ability to introduce DNA into rapidly dividing cells, such as skin cells, to replace the defective gene causing the disease and restore normal functioning of the affected cells. Krystal Biotech focuses on developing gene therapies for severe and rare diseases where effective treatments are often lacking. The company has several gene therapy products in development, including KB103 for the treatment of Epidermolysis bullosa, KB105 for the treatment of Netherton syndrome, and KB104 for the treatment of Heidelberg syndrome. KB103 is currently in phases 1 and 2 of clinical development and has the potential to become the first approved gene therapy product for treating Epidermolysis bullosa. Krystal Biotech also places a strong emphasis on collaboration with other companies and stakeholders in the biotechnology industry. The company has entered into a collaboration agreement with the international pharmaceutical company Bayer to develop a gene therapy platform for the treatment of serious eye diseases. In summary, Krystal Biotech's business model is based on the development and commercialization of gene therapy products for rare dermatological and genetic diseases. The company aims to improve the lives of patients with severe and rare diseases and seeks partnerships and alliances with other biotechnology companies and stakeholders in the industry to achieve this goal.

The expected revenue of Krystal Biotech is 513.61 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Krystal Biotech is 217.63 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Krystal Biotech is currently 44.39. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Krystal Biotech stock.

The price-to-sales ratio (P/S) of Krystal Biotech is currently 18.81. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Krystal Biotech stock.

The Eulerpool Quality Score for Krystal Biotech is 5/10.

The ISIN of Krystal Biotech is US5011471027. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Krystal Biotech is A2JH2F. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Krystal Biotech is KRYS. The ticker symbol is used to trade Krystal Biotech shares on the stock exchange.

Krystal Biotech paid dividends every year for the past 0 years.

Krystal Biotech is assigned to the 'Health' sector.

The dividends of Krystal Biotech are distributed in USD.

All fundamentals and in-depth analysis of Krystal Biotech

Our stock analysis for Krystal Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Krystal Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Krystal Biotech Stock
Krystal Biotech Revenue→
Krystal Biotech Stock
Krystal Biotech Net Income→
Krystal Biotech Stock
Krystal Biotech P/E→
Krystal Biotech Stock
Krystal Biotech P/S→
Krystal Biotech Stock
Krystal Biotech EBIT→
Krystal Biotech Stock
Krystal Biotech Dividend→
Krystal Biotech Stock
Krystal Biotech Directors Dealings→
Krystal Biotech Stock
Krystal Biotech Stocks→
Krystal Biotech Stock
Krystal Biotech Market capitalization→
Krystal Biotech Stock
Krystal Biotech Debt→
Krystal Biotech Stock
Krystal Biotech Liabilities→
Krystal Biotech Stock
Krystal Biotech Equity→
Krystal Biotech Stock
Krystal Biotech AAQS→
Krystal Biotech Stock
Krystal Biotech Employees→
Krystal Biotech Stock
Krystal Biotech ROE→
Krystal Biotech Stock
Krystal Biotech ROA→
Krystal Biotech Stock
Krystal Biotech ROCE→
Krystal Biotech Stock
Krystal Biotech News→
Krystal Biotech Stock
Krystal Biotech Analyst Price Targets→

Health Stocks

KT Medical Service CoKrsnaa DiagnosticsKubota Pharmaceutical Holdings CoKrishna Institute of Medical SciencesKukje Pharma CoKringle PharmaKukjeon Pharmaceutical CoKrebs Biochemicals and IndustriesKun Peng InternationalKPC PharmaceuticalsKura OncologyKowa CoAll Stocks A–Z →